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Deficient IgAl immune response to nasal cholera toxin subunit B in
primary IgA nephropathy. Twelve IgA nephropathy (IgAN) patients and
18 controls were immunized with novel protein antigens, cholera toxin
subunit B (CTB) via the nasal route and keyhole limpet hemocyanin
(KLH) subcutaneously. Antibody secreting cells and antibody response in
body fluids were determined by ELISPOT assay and ELISA, respectively.
Analysis of variance showed, in contrast to controls (P < 0.001), no
CTB-specific IgA response in the nasal washes of patients with IgAN.
Significantly lower numbers of CTB-specific antibody-secreting cells in
peripheral blood (P < 0.001) and CTB-specific antibodies in plasma (P <
0.005) were found in IgAN, both restricted to the IgAl subclass. The
proportions of CTB-specific IgAl-secreting cells in bone marrow aspirates
correlated significantly with the corresponding ratios in plasma, with
significantly lower values (P < 0.005) in IgAN as compared to controls.
These results support the existence of a 'mucosa-bone marrow axis' in
humans, but no dysregulation of this axis was found in IgAN. The deficient
mucosal IgA immune response to CTB observed in this study after
primary mucosal immunization indicates that patients with IgAN have a
defective immune response when challenged intranasally. These patients
may depend on more frequent and/or prolonged antigen encounter at
mucosal Sites before efficient mucosal immunity is established. Repeated
seeding of antigen-specific cells to secondary lympoid organs could result
secondarily in the relative hyperresponsiveness found in IgAN upon
reactivation by parenteral immunization.
Primary IgA nephropathy (IgAN) is a common form of primary
glomerulonephritis with a varied spectrum of clinical presenta-
tions, leading to progressive renal failure in a substantial propor-
tion of patients [1, 21. The disease is characterized by deposits of
igAl in the glonierular mesangium [3—8]. The mesangial IgA has
been found to consist at least in part of polymeric IgA (p-IgA) [5,
9—11]. Although increased plasma levels of IgAl and IgAl-
containing immune complexes are thought to be of pathogenetic
importance, the mechanism of the mesangial deposition remains
unclear [12]. The increased concentration of plasma IgAl appears
to he the result of an increased production of this isotype by the
bone marrow [13—16]. The niacromolecular IgA found in the
circulation also contains predominantly monomeric IgAl (m-
lgAi) [17, 18]. The pathogenetic significance of p-lgA in IgAN is
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still subject of controversy. In children p-IgA levels correlate with
bouts of macroscopic hematuria [19, 20], but in adults the
elevation of serum p-IgA and its correlation with disease activity
is less clear [5, 6, 15, 21—27].
Although it seems obvious that the stimulus for IgA production
is of mucosal origin, the responsible agent in IgAN and the site of
immunization remain to be elucidated. On the basis of the
association of episodes of macroscopic hematuria with infections
of mainly the upper respiratory tract [1], it is assumed that in
IgAN the mucosal immune system is stimulated by microbial
antigens. However, previous studies of IgA responses, both after
systemic and oral secondary immunization, in patients with IgAN
have provided conflicting results [28—34]. The mucosal immune
response after nasal immunization with novel or recall (viral)
antigens has not been studied in patients with IgAN.
Systemic immunization in humans results in the transient
appearance in the peripheral blood of B cells capable of sponta-
neous antigen-specific antibody production [35—37]. These anti-
body-secreting cells are considered to represent migrating B cells
on their way to their final destination in systemic lymphoid tissues,
including lymph nodes, spleen and bone marrow [38]. The ap-
pearance of antigen-specific antibody-secreting cells is followed by
a rise in specific serum antibodies produced mainly by bone
marrow plasmocytes [381. Antigen-specific antibody-secreting
cells in peripheral blood have also been detected after intranasal
immunization [39—41], extending the evidence for the concept of
a common mucosal immune system [42, 43]. According to this
concept, B cells activated at mucosal inductive sites, migrate via
the circulation to local but also to remote mucosal effector sites,
where they undergo final differentiation into plasmocytes.
Exposure of a mucosal surface to non-viable or live microbial
antigens (vaccines or infection) may result in a local and a
systemic immune response. Except for live antigens, an IgA
response is not regularly induced in the systemic compartment
[44]. Cholera toxin and its B subunit (CTB) have been shown to
induce not only strong mucosal IgA responses but also serum IgA
(and IgG) antibodies [45]. This is explained by the ability of the B
subunit to bind avidly to GM 1 ganglioside, its natural ligand
present on microfold cells overlying the mucosa associated lym-
phoid tissue (MALT) [46].
The routes of immunization and types of antigens that might
induce an effective immune response in the human bone marrow
have not been clarified. Repeated exposure to mucosal antigens
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may induce B-cells to migrate to mucosal and non-mucosal
lymphoid tissues such as the lymph nodes and spleen [47]. Upon
rechallenge, memory B cells may leave the lymph nodes and
disseminate the secondary response to the bone marrow where
they differentiate into plasma cells that secrete p-IgA antibodies
[301. The existence of such a 'mucosa-bone marrow axis' is
suggested by studies in experimental animals [48—50]. However,
there are no data available yet to support this axis in humans.
The high IgAl serum levels in patients with IgAN could either
be a primary hyperresponsiveness of the mucosal immune system
or a compensatory reaction of the systemic compartment to a
hypothetical hyporesponsivity of the MALT. To investigate the
hypothesis of a dysregulated 'mucosa-bone marrow axis' in pa-
tients with primary IgA nephropathy we studied the immune
response in both compartments of the IgA immune system after
primary and booster intranasal immunization. This study indicates
that patients with IgAN are not hyper- but hyporesponders when
they are immunized intranasally with CTB.
Methods
Human subjects
The study protocol was approved by the Ethical Committee of
the Leiden University Hospital. All individuals gave informed
consent. Twelve patients (11 males, mean age 36.5 years; range 26
to 52 years) with biopsy proven IgAN were studied. None of the
patients had clinical or laboratory evidence of Henoch-Schönlein
purpura, systemic lupus erythematosus, liver disease or received
immunosuppressive therapy. Kidney function was normal or
mildly impaired (creatinine clearance > 80 mI/mm). None of the
patients had macroscopic hematuria or proteinuria > 2 g/24
hours. As controls 18 healthy volunteers, (12 males, mean age 28.4
years; range 21 to 40 years) were recruited. Neither patients nor
controls had received the whole cell/B subunit, parenteral whole
cell cholera vaccine or had had clinical cholera previously. There
were no symptoms or signs of mucosal infection in the two weeks
preceding or during the study period. All subjects completed the
study.
Immunization protocol
Individuals were given 0.33 mg of recombinant CTB (provided
by JH) [371 per immunization intranasally by spray and 250 jg
KLH (Calbiochem, La Jolla, CA, USA) subcutaneously. Two
identical doses of CTB and KLH were given as booster immuni-
zation on days 14 and 28, respectively. Serum samples and
peripheral blood mononuclear cells (PBMC) were obtained on
days 0, 7, 21, 35 and 42. Two weeks after the second booster
immunisation (day 42) bone marrow samples were obtained from
the posterior iliac crest [13]. Nasal washes were collected on days
0, 7, 21 and 35. Both antigens were well tolerated and no
side-effects were noted.
Cells
Venous blood was collected in sterile, heparinized syringes,
PBMCs were isolated by centrifugation using a standard Ficoll-
Hypaque (Sigma Chemical Co., St. Louis, MO, USA) density
gradient. Bone marrow nucleated cells (BMNC) were processed
as previously described [13]. After lysis of contaminating red
blood cells and three washings, the cells were placed in complete
tissue culture media consisting of RPM! 1640 medium supple-
mented with L-glutamine (Gibco, Breda, The Netherlands) and
10% heat-inactivated fetal calf serum (zFCS) at a concentration
of 5 X 106 cells/mi. The number of viable cells was established by
trypan blue exclusion in a hemocytometer. The immunoglobulin-
producing cells were assayed immediately in the enzyme-linked
immunospot (ELISPOT) assay.
Body fluids
Serum samples were obtained from fresh venous blood after
overnight fast. At the same time nasal wash effluent was collected
after installation of 3 x 1 ml of sterile normal saline into each
nostril with the neck extended, remaining still for one minute.
Samples were immediately placed on ice, centrifuged (1200 rpm
for 10 mm at 4°C) and the supernatants collected. Samples were
stored frozen at —20°C until assayed.
ELISPOT assay
Total immunoglobulin and antigen-specific antibody-secreting
cells were enumerated using the ELISPOT technique as described
previously [51]. For the enumeration of immunoglobulin-secret-
ing cells, the wells of nitrocellulose-bottomed, 96-well Millititer
HA plates (Millipore, Bedford, MA, USA) were coated with
heavy chain specific, affinity purified goat F(ab')2 fragments
against human IgA, IgG or 1gM (Jackson, West Grove, PA, USA).
The capture antibodies for enumeration of immunoglobulin-
producing cells of the two IgA subclasses were mAb 69-11.4
(specific for IgAl) and mAb 16-512-H5 (specific for IgA2). The
quality, specificity and general usefulness in different body fluids
of these mAbs has been described [5, 52, 53].
Purified CTB (5 jkg/ml) and KLH (20 j.g/mI) were used as the
coating reagents in the antigen-specific ELISPOT. For the detec-
tion of CTB-specific antibody-secreting cells, individual wells of
the Millititer HA plates were precoated with 100 pJ of 6 /LM GM1
ganglioside (Sigma) in phosphate buffered saline, pH 7.4 (PBS)
overnight at 4°C. GMI precoated wells were subsequently coated
with 100 jLl of CTB overnight at 25°C. The next day remaining
binding sites were saturated with 150 tl of culture medium
containing 10% ZFCS for two hours at 37°C in a humidified
atmosphere with 5% CO2. Between the different incubations the
wells were washed three times and soaked for at least five minutes
using sterile PBS. After discarding the blocking solution, 100 tl of
cell suspension was dispensed into the wells at four different cell
densities (range, 6.25 105/ml to 5 106/ml) in duplicate. After
incubating the cells for four hours at 37°C and 5% C02, the plate
was washed three times with PBS and three times with PBS
containing 0.05% Tween 20 (PBST). Biotinylated heavy chain-
specific, affinity purified F(ab')2 fragments against human IgA,
IgG or 1gM (Tago, Burlirigame, CA, USA), appropriately diluted,
were added as secondary antibody.
Antigen-specific antibodies of the IgA subclasses were detected
by mAb 69-11.4 (for IgAl) and mAb 16-512-1-15 (for IgA2). After
overnight incubation at 4°C the wells containing the mAbs were
incubated with affinity purified, biotinylated goat anti-mouse IgG
for two hours at 37°C. After washing and soaking with PBST six
times, extravidin-conjugated alkaline phosphatase (Sigma) was
added to the wells to bind the secondary antibody for 60 minutes
at room temperature. Following a final wash (PBST and PBS 3
times, respectively) and soak in PBS the nitrocellulose-bottomed
wells were exposed to a chromogen substrate solution consisting
of 5-bromo-4-chloro-3-iridolyl phosphate toluidine salt (BCIP;
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Bio-Rad Lab, Richmond, CA, USA) and p-nitroblue tetrazolium
chloride (NBT; Bio-Rad) in 0.1 M NaHCO3 plus I mist MgCI2, pH
9.8. When spots reached maximal intensity, generally between 45
and 60 minutes, the reaction was stopped by thoroughly rinsing
the plates with water. Spots were counted under a stereomicro-
scope with X 40 magnification and expressed as number of
spot-forming cells (SFC) per 106 PBMCs or BMNCs added to the
wells. Appropriate control wells (GM1 ganglioside, culture me-
dium, irrelevant antigen) showed no spots. In preliminary exper-
iments we determined the optimal intranasal dose of CTB needed
to induce the appearance of CTB-specific ASC. In a group of five
volunteers a dose of either 0.33 or 1 mg induced an apparently
maximal response with a peak between five and nine days. Based
on these data we selected a dose of 0.33 mg CTB for nasal
immunization and a sampling period of seven days [43] after each
immunization.
EL ISA
Plasma and nasal washes were tested for total and antigen-
specific antibodies of the various isotypes by enzyme-linked
immunosorbent assay (ELISA). Polystyrene 96-well ELISA plates
(Greiner, Alphen a/d Rijn, The Netherlands) were coated, over-
night at room temperature, with 100 j.d/well of the capturing
antibody, appropriately diluted in PBS. Reagents were heavy
chain specific, affinity purified goat F(ab')2 fragments against
human IgA, IgG or 1gM (Jackson, West Grove, PA, USA). In the
IgA subclass ELISA the primary antibodies were subclass specific
mAb 69-11.4 (IgAl) and 16-512-H5 (IgA2). In the CTB-specific
ELISA the polystyrene plates were coated with 100 pJ of CTB (2.5
pg/mI) or KLH (10 .rg/ml) overnight at room temperature. After
three washings with PBST, non-specific binding sites were blocked
with PBST containing 1% bovine serum albumin.
Appropriate serial dilutions of serum or nasal wash samples
were added to duplicate wells and incubated for two hours at
37°C. Samples obtained at the different time points after immu-
nization were investigated in the same ELISA plate. Nasal wash
anti-CTB antibody levels were corrected for the influence of
dilution, which occurred when the specimen was obtained, by
dividing the antibody level by the total level of the corresponding
isotype by ELISA or the albumin concentration as determined by
rate nephelometry (Array Rate Nephelometer; Beckman, Brea,
CA, USA). In the ELISA for total immunoglobulin serial twofold
dilutions of a normal human serum pool (NHS) with known
concentrations of IgA, IgAl, IgA2, IgG and 1gM served as a
standard [53]. In the vaccine-specific ELISA's titers were ex-
pressed in arbitrary units per ml (AU/ml), relative to a standard
serum yielding high optical density (OD) values in ELISA for a
certain isotype. A different standard serum was chosen for each
isotype and used in a dilution series on each EL1SA plate. The
standard sera yielded increasing OD values in a dose dependent
fashion to values usually over 2.000.
Bound total immunoglobulin was detected by heavy chain-
specific, affinity-purified goat F(ab')2 fragments against human
IgA (for lgA, IgAl and lgA2), lgG and 1gM coupled to biotin
(Tago). Vaccine-specific antibodies were detected by optimal
dilutions of biotinylated goat anti-human IgA, IgG, 1gM (Tago)
and mAb 69-11.4 (IgAl) or mAb 16-512-1-15 (IgA2) as secondary
antibodies and incubated for two hours at 37°C. The anti-IgA
subclass mAbs were detected by biotinylated, affinity-purified goat
anti-mouse IgG. Consecutive incuhations followed with streptavi-
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Fig. 1. CTB-specific IgA immune response in nasal wash. IgA immune
response in nasal wash effluents of patients with IgAN (Ei) and controls
(LII) following immunization with CTB intranasally on days 0, 14 and 28.
Response is defined as the fold increase in the ratio of CTB-specific IgA
titer/total IgA (AU/J.Lg) relative to the preimmunization ratio. Results are
expressed as geometrical means SEM, and showed a deficient local
immune response in patients with IgAN, reaching significance (°°P <
0.0005) following the third immunization as compared to controls. No
significant differences were found with respect to the total IgA/albumin
ratios (gI.tg) between groups or with time, indicating results were not
biased by dilutional differences in obtaining the specimen.
dine conjugated to horseradish peroxidase (Zymed; Sanbio By,
Uden, The Netherlands) and enzyme substrate (2,2'-azino-bis
[3-ethylbenzthiazoline-6-sulfonic acid]; Sigma) containing 0,0075%
H202. Between each step the wells were washed three times
(PBST).
Optical density (OD) was measured at 415 nm on a microplate
reader (Bio-Kinetics Reader EL 312e, Biotek Instruments Inc.,
Winooski, VT, USA). Concentrations or titers were obtained by
interpolation on the standard curves using a four parameter
modeling procedure (KinetiCalc, EIA Application Software). The
final concentrations in each sample were calculated as the mean of
the results at the proper sample dilutions yielding ODs in the
linear parts of the calibration curves.
Statistical analysis
All statistical calculations were performed using the SPSS for
Windows Release 6.0 software package. The ELISA-titers and the
SEC-numbers showed a skewed distribution and were trans-
formed logarithmically prior to analysis. The two way ANOVA
with repeated measurements was used to study the effect of both
group (patient vs. control) and time after immunization. Post hoc
comparisons were made using Schcffe's procedure. Simple linear
regression was used to determine correlation between the number
of SFC and antibody concentrations or titers. Significance was
accepted at the 0.05 level. Results are expressed as geometrical
mean SFM.
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Results
Antibody in nasal washes after intranasal immunization
The CTB-specific IgA antibody response in nasal washes after
intranasal immunization was determined by specific ELISA. Sam-
ples obtained at the different time points for each subject were
examined in the same ELISA plate relative to an internal
standard and expressed in arbitrary units per ml (AU/mi). Pre-
immunization titers of CTB-specific IgA were all in the lower
linear parts of the standard curves and not significantly different
between the two groups. The local IgA immune response after
immunization for each individual was defined as the fold increase
in titer relative to baseline.
To standardize for dilutional differences in obtaining the spec-
imen, the titers of CTB-specific IgA antibodies (AU/mI) in the
nasal washes were related to the corresponding concentration of
total IgA (g/ml). The IgAl-antiCTB over total IgAl ratio
(AU/tg) after each challenge relative to pre-immunization values
is plotted against time in Figure 1. In contrast to controls, patients
with IgAN showed no local IgA immune respons after the first
(day 14) and second (day 28) rechallenge. This difference was
significant (P < 0.0005) after the second rechallenge as compared
to controls. The total IgA over albumin ratios did not vary
significantly in time and no significant differences between the two
groups were found (Fig. 1). This indicated that the results were
not biased by the method used to standardize for differences in
dilution, occurring when samples were obtained.
Circulating anibody-secreting cells after subcutaneous or intranasal
immunization
The frequencies of antigen-specific spot forming cells (SFC)
occurring in peripheral blood were measured before and after
intranasal (CTB) and subcutaneous (KLH) immunization in
patients with IgAN and controls by ELISPOT assays.
The numbers of SFCs per 106 PBMC are plotted against time
for CTB in Figure 2 and for KLH in Figure 3. Analysis of variance
revealed a significant (P < 0.0001) increase in the numbers of
specific 1gM, IgG, IgA, IgAl and IgA2 SFCs in peripheral blood
both after intranasal immunization with CTB (Fig. 2) and subcu-
taneous immunization with KLH (Fig. 3).
After primary intranasal immunization with CTB the numbers
of CTB-specific 1gM or IgG SFCs were not significantly different
between patients and controls (P 0.85 and P = 0.23, respec-
tively). However, the number of CTB-specific lgA SFCs was
significantly (P < 0.005) lower in patients. The number of
CTB-specific SFCs of the IgAl subclass was significantly (P <
0.0001) lower in patients, while no significant (P = 0.84) differ-
ence was found between the groups with respect to CTB-specific
SFC of the lgA2 subclass. The number of CTB-specific IgA2 SFCs
rose significantly in time, but was strikingly low compared to the
IgAl response in controls. The IgAl-ratio (IgAl/{IgAl+IgA2})
in patients was also significantly (P < 0.005) lower in patients.
Comparable results were found after the first and second booster
immunization (Fig. 2). Since peak responses have been shown to
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Fig. 2. Nasal immunization. Frequencies of 1gM (left panels, •), IgG (left panels, ::), IgA (left panels, ), IgAl (right panels, LII) and IgA2 (right
panels, •) isotypes of CTB-specific spot forming cells (SFCs) in controls and patients with IgAN measured in PBMCs isolated before immunization or
seven days following each immunization with CTB intranasally on days 0, 14 and 28. The ratios (•) of IgAl SFCs over {IgAl + IgA2} SFCs are also
shown in the right panels. Results, expressed as geometrical means SEM, showed significantly (P < 0.0001) lower numbers of CTB-specific SFCs in
patients with IgAN, restricted to the IgAl subclass. P values from Scheffe's procedure are *P < 0.05, **D < 0.005).
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occur earlier after booster immunization [54], our results obtained
after the second (day 21) and third (day 35) dose probably reflect
the descending limb of the immune response.
After primary subcutaneous immunization with KLH the num-
bers of KLH-specific 1gM (P = 0.27), lgG (P = 0.13), IgA (P =
0.93), IgAl (P = 0.81) and IgA2 (P = 0.26) SFCs were not
significantly different between patients and controls. Subsequent
booster immunizations also yielded no significant differences in
the numbers of KLH-specific SFCs between the two groups (Fig.
3).
The numbers of total immunoglobulin secreting cells of the
different isotypes showed no significant differences between pa-
tients and controls during the course of time (Fig. 4).
Specific antibodies in plasma after systemic or intranasal
immunization
The antigen-specific antibody response in plasma after intrana-
sal (CTB) and subcutaneous (KLH) immunization was deter-
mined by specific ELISAs. Samples obtained at the different time
points for each subject were examined in the same ELISA plate
relative to an internal standard and expressed in arbitrary units
per ml (AU/mi). Pre-immunization titers of CTB-specifIc and
KLH-spccific isotypes were all in the lower linear parts of the
standard curves and not significantly different between the two
groups. The antibody titers for each individual was expressed as
the fold increase in titer relative to baseline and plotted against
time.
Analysis of variance showed a significant (P <0.0001) increase
in the IgG, IgA (Fig. 5) and IgAl (Fig. 6) titers against both CTB
and KLH after intranasal and subcutaneous immunization, re-
spectively.
Comparison between the two groups showed a significantly
(P < 0.001) lower CTB-specific IgA immune response in plasma
after nasal immunization in patients with IgAN (Fig. 5). The
CTB-specific IgAl immune response was also found to be signif-
icantly (P < 0.005) lower in patients (Fig. 6). No differences were
found between the groups with respect to the CTB-specific 1gM,
IgG and IgA2 immune responses.
After subcutaneous immunization with KLH no significant
differences were found in the KLH-specific immune responses
between patients and controls. The results for IgA and lgG are
plotted against time in Figure 5.
Correlation between ASC in bone marrow and antibodies in
plasma
Correlation between the number of total immunoglobulin and
CTB-specific SFCs in bone marrow aspirates and the corespond-
ing concentration or titer in plasma was examined two weeks after
the last immunization (day 42). At this time virtually no CTB-
specific SFC's were found in the peripheral blood. The lack of
correlation between PBMC and BMNC indicated that there was
no significant contamination of the bone marrow aspirates by
peripheral blood.
Analysis by simple linear regression showed that there was a
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Fig. 3. Subcutaneous immunization. Frequencies of 1gM (left panels, U), IgG (left panels, lii), IgA (left panels, U), IgAl (right panels, LI) and IgA2
(right panels, U) isotypes of KLH-specific spot forming cells (SFCs) in controls and patients with IgAN measured in PBMCs isolated before
immunization or seven days following each immunization with KLH subcutaneously on days 0, 14 and 28. The ratios (•) of IgAl SFCs over {IgAl +
IgA2} SFCs is also shown in the right panels. Results, expressed as geometrical means SEM, showed no significant differences in KLH-specific SFCs
of the various isotypes between patients with IgAN and controls.
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significant correlation between the number of IgA (r = 0.67; P <
0.005) and IgAl (r = 0.76; P < 0.001) SFCs in the bone marrow(ELISPOT) and the concentration of IgA and IgAl in plasma
(ELISA) on day 42, respectively. Patients with IgAN had signifi-
cantly higher numbers of total IgA (P < 0.05) and IgAl (P < 0.01)
SFCs in bone marrow aspirates and significantly higher concen-
trations of IgA (P < 0.01) and IgAl (P < 0.005) in plasma. These
results are shown in Figure 7A.
There was also a significant correlation between the proportion
(SFC/SFC) of IgA-antiCTB/total-lgA (r = 0.68; P < 0.001) and
lgAl-antiCTB/total-IgAl (r = 0.62; P < 0.001) in the bone
marrow (ELISPOT) and the IgA-antiCTB/total-IgA and IgAl-
antiCTB/total-IgAl ratios (AU/jig) in plasma (ELISA) on day 42.
Patients with IgAN had significantly lower ratios of CTB-specific
IgA/total-IgA (P < 0.05) and CTB-specifIc lgAl/total-IgAl (P <
0.005) in bone marrow aspirates, and also significantly lower ratios
of IgA-antiCTB/total-IgA (P < 0.005) and IgAl-antiCTB/total-
IgAl (P < 0.005) in plasma. These results are shown in Figure 7B.
Discussion
Elevated plasma levels of IgAl are thought to play an essential
role in the pathogenesis of IgAN [14], and are the consequence of
an increased production, in which the hone marrow may be the
predominant site [13, 15, 16]. The clinical association of exacer-
bations of the disease with upper respiratory tract infections
suggests that the trigger for the increased IgAl production is
frequently in the nasopharynx [1]. Furthermore, a significantly
higher proportion of IgAl -producing cells was found in the tonsils
of patients with IgAN [55—57]. In contrast, the histology, the
percentage of IgA plasma cells, and the IgA subclass distribution
in the small bowel were found to be normal [58, 59] or showed a
reduced percentage of IgA plasma cells [60] as compared to
controls. However, it is still unclear how upper respiratory infec-
tions can induce an overproduction of IgAl in the bone marrow of
IgAN patients. Such a sequence of events would require a link
between the mucosal and systemic compartments of the IgA
immune system through a hypothetical "mucosa-bone marrow
axis" [13, 15 ]. Evidence for the existence of such an axis has so far
only been reported in experimental animals [48—50].
The present study is the first, to our knowledge, to provide
evidence for the existence of a mucosa-hone marrow axis in
humans. Both in the heathy controls, and in the IgAN patients we
have demonstrated in this study the presence of specific IgAl
antibody-producing cells in the bone marrow after nasal antigen
presentation. This suggests that mucosal presentation of antigens
in humans not only leads to a dissemination of the immune
response to distant mucosal sites as defined in the concept of the
common mucosal immune system [42, but also to the systemic
compartment of the IgA system, especially the bone marrow, the
predominant site of plasma IgA production in humans [611. In the
current study we chose CTB as the antigen because of its strong
immunogenicity. Apart from a small previous study [37], this is the
first study demonstrating the good mucosal immunogenieity of
nasal immunization with CTB in humans. The frequency of
2000
1500
IgAN ' 1000
0
500
0
2000
1500
Control 1000
500
0
Isotypes
Time, weeks
0
0
(0Q
0
U-
C,)
0
0
0
U-
C,)
1000
750
500
250
0
1000
750
500
250
0
IgA subclasses
Time, weeks
100
75 (3_
50 .0
25
0
100
75(
50
0
25
0
Fig. 4. Total immunoglobulin secreting cells. Frequencies of total 1gM (left panels, U), IgG (left panels, Li), IgA (left panels, Li), IgAl (right panels, Li) and
IgA2 (right panels, U) spot forming cells (SFC5) in controls and patients with tgAN measured in PBMCs isolated before immunization or seven days following
each immunization on days 0, 14 and 28. The ratios (•) of IgAl SFCs over {IgAl + lgA2} SFCs is also shown in the right panels. Results, expressed as
geometrical means SEM, showed no significant differences in immunoglobulin-secreting cells of the various isotypes between patients with IgAN and controls.
responders (> 4-fold increment in plasma titer) in the control
group was 16%, 94% and 100% after the first, second and third
immunization, respectively. The CTB-specific secretory IgA re-
sponse in controls was almost exclusively of the IgAl subclass as
was described previously for serum antibodies after oral immuni-
zation with CTB [54]. Such an antigen would provide us the best
opportunity to demonstrate the communication of a mucosal
antigen presentation to a bone marrow immune response.
In the light of previous immunization studies in IgAN patients,
which have provided evidence of both a normal [29, 31, 33, 34]
and an increased [30—32] IgA immune reponse, sometimes lim-
ited to the relevant subclass IgAl [30] or polymeric forms [31], we
had expected that the IgAl anti-CTB response would be higher in
our patients than in the controls. Moreover, our hypothesis was
that especially the immune response in the patients' bone marrow
after nasal immunization would be significantly higher, reflected
by increased numbers of IgAl antibody-secreting cells, and in-
creased levels of plasma IgAl antibodies. Surprisingly, we found
significantly lower immune responses in the IgAN patients, not
only in the systemic compartment (bone marrow and plasma), but
also locally in the nasal secretions, and in the transient circulating
antibody secreting cells. Therefore no apparent dysregulation of
the mucosa-bone marrow axis was found in patients with lgAN.
As an internal control, all subjects were concurrently systemi-
cally immunized with KLH. In contrast to the decreased immune
response to nasal CTB, the systemic immune response to paren-
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Fig. 6. CTB-specific IgAl immune response in plasma. IgA I immune
response in plasma of patients with IgAN (•) and controls (E) following
immunization with CTB intranasally on days 0, 14, 28. Response defined
as fold increase in titer (AU/mi) relative to preimmunization. Results,
expressed as geometrical means 5EM, showed a significantly (P < 0.001)
lower CTB-specific IgAl immune response in patients with IgAN. P values
from Scheffe's procedure are *p < 0.05.
teral KLH was not significantly different in patients compared
with healthy controls. These unexpected findings raise the ques-
tion why there is a discrepancy in the induced immune response to
nasal CTB and parenteral KLH in patients in the present study,
*
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Fig. 5. Antigen-specific immune response in plasma. Specific IgA (left panels) and IgG (right panels) immune response in plasma of patients with IgAN(•) and controls (LI) following immunization with CTB (intranasal) and KLH (subcutaneous) on days 0, 14, 28. Response defined as fold increase in
titer (AU/mI) relative to preimmunization. Results, expressed as geometrical means SEM, showed a significantly (P < 0.001) lower CTB-specific IgA
immune response in plasma in patients with IgAN as compared to volunteers. No significant differences were found between the groups with respect
to the CTB-specific IgG and KLH-specifie IgA and IgG responses. P-values from Scheffe's procedure are *p < 0.05, **p < 0.005).
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while some earlier studies with recall antigens using the oral [32]
or parenteral [30, 311 immunization route have suggested an
exaggerated systemic IgA immune response in IgAN patients. A
possible reason is that the antigens employed in the current study
are both "neo-antigens" to which our subjects had in all proba-
bility not been previously exposed. This factor makes the current
study different from the published immunization studies in which
recall antigens were used. A hypothesis explaining the different
findings using neo-antigens could be that IgAN patients have a
deficient primary nasal immune response, resulting in a delayed
activation of immunocompetent cells. Interestingly, recall nasal
priming with tetanus toxoid and subsequent parentcral boostering
resulted in lower serum IgAl antibodies (and also a smaller
increase) in IgAN patients before and after parenteral rechallenge
[341. An indication of IgA-specific suppression after oral recall
immunization has also been reported. Elevated serum IgA anti-
bodies prior to immunization decreased to normal levels after-
ward, suggesting some degree of in vivo hyporesponsiveness in
patients with IgAN [33]. Such a deficient primary immune re-
sponse may then lead to persistence or recurrence of the antigenie
stimulus in patients, whereas healthy individuals succeed in effec-
tive elimination or exclusion of antigen. The resulting ongoing or
repeated stimulation of the immune response may eventually lead
to overproduction of IgA antibodies in the systemic compartment,
and an increased number of memory cells. The previously re-
ported increased IgA immune response to recall antigens may be
the reflection of this increased level of immunological memory
[30—32].
It is relevant to note that all of the earlier studies that found
evidence for a significantly higher systemic IgA [32] or IgA1 [301
immune response, also reported higher preimmunization levels in
IgAN patients. When the peak levels of IgA antibodies after
immunization are related to these already elevated baseline levels,
the relative increase in titers is not augmented in patients [301.
The higher levels of naturally occurring antibodies to certain
types of antigens and the high total serum IgA in IgAN suggest
that a wide range of antigenic specificities are activated in these
patients. The most consistent observation has been that the
abnormalities in the IgA system in patients with IgAN are
predominantly or exclusively restricted to the IgAl subclass. This
restriction could be explained by the chemical nature of the
immunogen, or a second explanation would be that the IgAl
response is determined by the site of exposure to the antigen [44].
This would mean that patients with IgAN are more heavily
exposed, in frequency or duration, to antigens that induce an IgAl
antibody response. On the other hand, in IgAN, mucosal abnor-
malities have so far mainly been found in the oropharyngeal
region [55—57].
A third possibility is a selective dysregulation of IgAl-produc-
ing B-lymphocytes in patients with IgAN. It is tempting to
speculate that the deficient mucosal and systemic IgAl response
we found in IgAN patients with nasal CTB is the consequence of
inadequate antigen presentation (such as by dendritic cells) or an
abnormality in T-cell regulatory mechanisms governing the com-
mon mucosal immune system and seeding of primed B-cells to the
systemic compartment.
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Fig. 7. Correlation between bone marrow and plasma after nasal immunization. (A) Correlation between the number of total IgA (r = 0.67,P < 0.005)
or IgAl (r = 0.76, P < 0.001) SFCs in bone marrow aspirates (SF/l06 BMNC) and plasma concentration of IgA or IgAl (pg/mI) two weeks after the
last immunization. Results (transformed to their natural logarithms) showing significant correlation between bone marrow and plasma, with significantly
higher total IgA and IgAl (P < 0.01) values in IgAN, both in bone marrow aspirates and plasma. (B) Correlation between IgA-anti-CTB/total-IgA (r =
0.68, P < 0.001) and IgAl-anti-CTB/total-IgAl (r = 0.62, P < 0.001) ratios (SFC/SFC) in bone marrow aspirates and corresponding ratios (AU/pg)
in plasma. Results (natural logarithms) showed significantly (P < 0.005) lower CTB-specific IgA and IgAl values in patients with IgAN, both in bone
marrow aspirates and plasma.
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In summary, the data indicate that patients with IgAN have a
deficient primary mucosal immune response to intranasally ad-
ministered CTB, limited to the IgAl subclass. Future studies will
have to show whether the current findings also pertain to other
antigens. Studies are in progress to elucidate whether there is a
discrepancy between the induced mucosal and systemic IgA
immune response to repeated nasal challenge by viral recall
antigens in patients not primed by previous parenteral immuni-
zation.
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